Emmanuel Bachy

机构：Lyon 1 Université, Centre National de la Recherche Scientifique, Inserm, Hospices Civils de Lyon, Centre International de Recherche en Infectiologie

发表论文 540 篇 · 总被引 11640 次 · h-index 51

代表论文

• Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial (2025 · The Lancet · 被引 16)
• Axi-cel delivers similar outcomes regardless of ASCT-eligibility in second line R/R LBCL: Combined data from ZUMA-7 and ALYCANTE (2025 · Blood · 被引 2)
• Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium (2025 · Blood · 被引 1)
• FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma (2025 · Journal of Clinical Oncology · 被引 1)
• Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with Relapsed/Refractory follicular lymphoma (R/R FL): Phase 1/2 study extended follow-up Results (2025 · Blood · 被引 1)
• Outcomes and treatment patterns of patients with primary mediastinal b-cell lymphoma after CAR-t cell therapy failure : A descar-t analysis (2025 · Blood · 被引 1)